# Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026

- Link: https://www.thailand-business-news.com/pr-news/dizal-to-present-emerging-data-on-zegfrovy-in-non-small-cell-lung-cancer-at-wclc-2026
- Published: 2026-08-21T15:03:00+07:00
- Author: PR Newswire

|   |

SHANGHAI, Aug. 21, 2026 /PRNewswire/ — Dizal (SSE: 688192), a biopharmaceutical 
company committed to developing novel medicines for the treatment of cancer and 
immunological diseases, announced today that the latest clinical data on its novel
epidermal growth factor receptor (EGFR) inhibitor ZEGFROVY^(®) (sunvozertinib) in
non-small cell lung cancer (NSCLC) will be presented at the 2026 World Conference
on Lung Cancer (WCLC) from September 12 to 15 in Seoul, Republic of Korea.

ZEGFROVY is approved in China and the U.S. for the treatment of adult patients with
locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations (exon20ins),
whose disease has progressed on or after platinum-based chemotherapy. In addition,
with positive results from WU-KONG28, a multinational randomized Phase 3 study in
treatment naïve patients, the Supplemental New Drug Application (sNDA) of ZEGFROVY
as first-line treatment has been submitted to China Center for Drug Evaluation (
CDE) and the US Food and Drug Administration (FDA). On July 14, Dizal announced 
that it entered into an exclusive license agreement granting AstraZeneca global 
rights to develop and commercialize ZEGFROVY. The transaction is expected to close
in the second half of 2026.

At WCLC 2026, Dizal will present the latest findings from a study evaluating ZEGFROVY
as adjuvant treatment in patients with resected stage IB-IIIB EGFR exon20ins NSCLC.
Promising efficacy results strengthen its potential as an earlier treatment option.
No new safety signals have been observed. Based on these findings, a randomized 
pivotal study is ongoing.  

In addition, Dizal will report updated data from a Phase 2 study evaluating ZEGFROVY
in combination with Anlotinib as first-line treatment for NSCLC with EGFR sensitizing
mutations and co-mutations. This oral chemotherapy-free combination regimen continues
to exhibit robust anti-tumor activity and a manageable safety profile.

The details of the presentation are shown below:

  |

**Lead Author**

  |

**Abstract Title**

  |

**Presentation Details**

  |  
 |

Prof. Chang Chen

  |

Efficacy and Safety of Sunvozertinib as Adjuvant 
Treatment in Resected Stage IB-IIIB EGFR Exon 20 Insertion Mutated NSCLC

  |

Abstract Number: P1.159

Poster Session

10:30 AM – 12:00 PM (KST / 
UTC +9), Sep 13, 2026

  |  
 |

Prof. Yongchang Zhang

  |

Sunvozertinib Plus Anlotinib as First-line Treatment for 
NSCLC with EGFR Sensitive Mutations and Co-mutations: Updated Phase II Data

  |

Abstract Number: P3.207

Poster Session

9:30 AM – 11:00 AM (KST / 
UTC +9), Sep 15, 2026

  |

**About ZEGFROVY****^(® )****(sunvozertinib)**

ZEGFROVY is an irreversible EGFR inhibitor targeting a wide spectrum of EGFR mutations
with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for 
the treatment of adult patients with locally advanced or metastatic non-small cell
lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion
mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy.
The approval in China is based on the results of the pivotal WU-KONG6 study in platinum-
based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported
by the results of WU-KONG1 Part B, a multinational pivotal study investigating the
efficacy and safety of ZEGFROVY in the same indication. The sNDA for ZEGFROVY as
first-line treatment in NSCLC patients with EGFR exon20ins has been submitted to
the China Center for Drug Evaluation (CDE) and US Food and Drug Administration (
FDA), supported by WU-KONG28 study results. Both China CDE and the US FDA have granted
Breakthrough Therapy Designation to ZEGFROVY in this setting.

In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC
patients with EGFR sensitizing, T790M, and uncommon mutations, as well as HER2 exon20ins.
ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The
most common drug-related TEAEs (treatment-emergent adverse events) were Grade 1/
2 in nature and clinically manageable.

**About Dizal**

Dizal is a biopharmaceutical company, dedicated to the discovery, development and
commercialization of differentiated therapeutics for the treatment of cancer and
immunological diseases. Dizal’s late-stage portfolio includes two approved drugs
and three investigational drugs in late-stage development. ZEGFROVY is approved 
in both the U.S. and China, for the treatment of NSCLC with EGFR exon20ins. Golidocitinib
is approved in China for the treatment of relapsed and refractory peripheral T cell
lymphoma. Birelentinib, a BBB-penetrant LYN/BTK dual inhibhitor, is currently in
pivotal studies for various hematological diseases. DZD6008, a 4^(th) generation
EGFR TKI, and GW5282 are in post Proof-of-Concept studies. To learn more about Dizal,
please visit [www.dizalpharma.com](http://www.dizalpharma.com/), or follow us on
[LinkedIn](http://www.linkedin.com/company/dizal-pharma) or [X](https://twitter.com/Dizal_Global).

**Forward-Looking Statements**

This news release may contain certain forward-looking statements that are, by their
nature, subject to significant risks and uncertainties. The words "anticipate", "
believe", "estimate", "expect", and "intend" and similar expressions, as they relate
to Dizal, are intended to identify certain forward-looking statements. Dizal does
not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions,
expectations, estimates, projections, and understandings of the management of Dizal
with respect to future events at the time these statements are made. These statements
are not a guarantee of future developments and are subject to risks, uncertainties,
and other factors, some of which are beyond Dizal’s control and are difficult to
predict. Consequently, actual results may differ materially from information contained
in the forward-looking statements as a result of future changes or developments 
in our business, Dizal’s competitive environment, and political, economic, legal,
and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct
or update the forward-looking statements contained on this site; and (b) no liability
in the event that any of the forward-looking statements does not materialize or 
turnout to be incorrect.

**Contacts**

Investor Relations: [ir@dizalpharma.com](https://www.thailand-business-news.com/pr-news/ir@dizalpharma.com)

Business Development: [bd@dizalpharma.com](https://www.thailand-business-news.com/pr-news/bd@dizalpharma.com)
Media Contact: [pr@dizalpharma.com](https://www.thailand-business-news.com/pr-news/pr@dizalpharma.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 ](http://www.prnasia.com/story/archive/5026480_CN26480_0?rand=184833)
